Dr. Reddy’s Laboratories (DRL), on Thursday, reported a net profit of Rs.690.38 crore for the second quarter of this fiscal, up by 69.41 per cent over the corresponding period last year. The net profit was Rs.407.44 crore for the same period in the last fiscal. The growth is largely driven by global generic sales in North America, Russia and other emerging markets, according to the company.
The company’s revenue for the quarter stood at Rs.3,357.45 crore as against Rs.2,880.85 crore in the second quarter of previous year. The revenue from global generics was Rs.2,650 crore, an increase of 32 percent over a year ago period. The company’s revenue from Indian market stood at Rs 421 crore, a year over year growth of 8.5 percent.
